HB 267 (see companion bill SB 1328) – Hawaii
Introduced: 2019 Status: Inactive / Dead
Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase …
HB 283 – Mississippi
Introduced: 2019 Status: Inactive / Dead
An Act To Create The “prohibition On Price Gouging For Essential Drugs Act”; To Define “price Gouging” And Certain Other Terms; To Prohibit Manufacturers And Wholesale Distributors Of Essential Generic Drugs From Engaging In Price …
HB 2882 – Illinois
Introduced: 2019 Status: Inactive / Dead
GENERIC DRUG PRICING. Creates the Pharmaceutical and Health Affordability: Restrictions on Manufacturers’ Amoral Behavior Through Reasonable Oversight Act. Provides that a manufacturer or wholesale drug distributor shall not engage in price gouging in the sale of …
HB 3031 – Texas
Introduced: 2021 Status: Inactive / Dead
Relating to prohibited billing practices by certain health care providers. Provides a hospital, treatment facility, mental health facility, or health care professional may not flagrantly overcharge a patient or third party payor for a treatment …
HB 3957 – Illinois
Introduced: 2023 Status: Enacted
Creates the Pharmaceutical and Health Affordability: Restrictions on Manufacturers’ Amoral Behavior through Reasonable Oversight Act. Provides that a manufacturer or wholesale drug distributor shall not engage in price gouging in the sale of an essential …
HB 4543 – West Virginia
Introduced: 2020 Status: Enacted
Relating to insurance coverage for diabetics. Cost sharing for a 30-day supply of a covered prescription insulin drug shall not exceed $100 for a 30-day supply of a covered prescription insulin, regardless of the quantity …
HB 4554 (see companion bill SB 577) – West Virginia
Introduced: 2020 Status: Inactive / Dead
Relating to insurance coverage for insulin. The purpose of this bill is to limit the amount that an insured person is required to pay for his or her insulin prescription to $100 per 30-day supply.
HB 4900 – Illinois
Introduced: 2018 Status: Inactive / Dead
ILLINOIS GENERIC DRUG PRICING FAIRNESS ACT: Provides that a manufacturer or wholesale drug distributor shall not engage in price gouging in the sale of an essential off-patent or generic drug. Provides that the Director of …
HB 502 – Kentucky
Introduced: 2019 Status: Inactive / Dead
Create new sections of KRS Chapter 217 to define terms; require the Cabinet for Health and Family Services to annually compile a list of certain prescription drugs deemed to be essential to treating diabetes and …
HB 5095 – Rhode Island
Introduced: 2019 Status: Inactive / Dead
Prohibits price-gouging of prescribed drugs or pharmaceuticals in times of market emergency or market shortages and makes violators guilty of a felony and subject to injunctive relief.
HB 5108 – Michigan
Introduced: 2019 Status: Inactive / Dead
Health; pharmaceuticals; increase of wholesale acquisition cost of prescription drugs; require manufacturers of prescription drugs to provide notice under certain circumstances. Amends 1978 PA 368 (MCL 333.1101 – 333.25211) by adding secs. 17748e, 17748f & …
HB 5109 – Michigan
Introduced: 2019 Status: Inactive / Dead
Consumer protection; unfair trade practices; prescription drugs; prohibit manufacturers from charging excessive prices or unconscionable increases in wholesale acquisition costs, and require attorney general to investigate violations. Amends sec. 3 of 1976 PA 331 (MCL …
HB 5111 – Rhode Island
Introduced: 2023 Status: In Process
Makes it a felony to price gouge prescriptions or pharmaceuticals in time of a shortage.
HB 53 – Illinois
Introduced: 2019 Status: Inactive / Dead
Amends the Illinois Food, Drug and Cosmetic Act. Requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly …
HB 5690 (see companion bill SB 900) – Michigan
Introduced: 2018 Status: Inactive / Dead
PROHIBIT MANUFACTURERS FROM CHARGING EXCESSIVE PRICES OR UNCONSCIONABLE INCREASES IN WHOLESALE ACQUISITION COSTS: A manufacturer of prescription drugs that is engaged in the conduct of trade or commerce shall not charge an excessive price for …
HB 62 – Delaware
Introduced: 2021 Status: In Process
An Act to amend Title 6 of the Delaware code relating to the prohibition of excessive and unconscionable prices for prescription drugs.